JCI Insight (Nov 2021)

HIV infection drives interferon signaling within intestinal SARS-CoV-2 target cells

  • Rabiah Fardoos,
  • Osaretin E. Asowata,
  • Nicholas Herbert,
  • Sarah K. Nyquist,
  • Yenzekile Zungu,
  • Alveera Singh,
  • Abigail Ngoepe,
  • Ian M. Mbano,
  • Ntombifuthi Mthabela,
  • Dirhona Ramjit,
  • Farina Karim,
  • Warren Kuhn,
  • Fusi G. Madela,
  • Vukani T. Manzini,
  • Frank Anderson,
  • Bonnie Berger,
  • Tune H. Pers,
  • Alex K. Shalek,
  • Alasdair Leslie,
  • Henrik N. Kløverpris

Journal volume & issue
Vol. 6, no. 16

Abstract

Read online

SARS-CoV-2 infects epithelial cells of the human gastrointestinal (GI) tract and causes related symptoms. HIV infection impairs gut homeostasis and is associated with an increased risk of COVID-19 fatality. To investigate the potential link between these observations, we analyzed single-cell transcriptional profiles and SARS-CoV-2 entry receptor expression across lymphoid and mucosal human tissue from chronically HIV-infected individuals and uninfected controls. Absorptive gut enterocytes displayed the highest coexpression of SARS-CoV-2 receptors ACE2, TMPRSS2, and TMPRSS4, of which ACE2 expression was associated with canonical interferon response and antiviral genes. Chronic treated HIV infection was associated with a clear antiviral response in gut enterocytes and, unexpectedly, with a substantial reduction of ACE2 and TMPRSS2 target cells. Gut tissue from SARS-CoV-2–infected individuals, however, showed abundant SARS-CoV-2 nucleocapsid protein in both the large and small intestine, including an HIV-coinfected individual. Thus, upregulation of antiviral response genes and downregulation of ACE2 and TMPRSS2 in the GI tract of HIV-infected individuals does not prevent SARS-CoV-2 infection in this compartment. The impact of these HIV-associated intestinal mucosal changes on SARS-CoV-2 infection dynamics, disease severity, and vaccine responses remains unclear and requires further investigation.

Keywords